Forecast: Healthcare Expenditure on Pharmaceuticals and Medical Non-Durable Goods in France

In 2023, healthcare expenditure on pharmaceuticals and medical non-durable goods in France was 38.94 billion euros, marking a year-on-year increase of 0.87%. Over the past five years, the compound annual growth rate (CAGR) has averaged 1.41%, indicating consistent growth amid fluctuations. From 2013 to 2018, the growth rates varied with some years showing declines. However, post-2018, a steady upward trend resumed, particularly notable in 2020 with a significant surge due to the pandemic-related impacts.

Forecasts for 2028 suggest a continued rise to 40.57 billion euros, with a projected 5-year CAGR of 0.65%, reflecting moderate growth. Factors such as aging population, advancements in healthcare technology, and policy changes in drug pricing and availability could influence future expenditure patterns, while ongoing COVID-19 implications also require close monitoring.